![Mark Goldsmith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 156 M $ al 31/05/2026
Mark A. Goldsmith was the founder of Cogentus Pharmaceuticals, Inc., founded in 2006, where the titles held included Chairman, President & Chief Executive Officer from 2006 to 2009.
Dr. Goldsmith is the founder of Revolution Medicines, Inc., founded in 2014, holding the titles of Chairman, President & Chief Executive Officer since 2020.
The current job is Director at Nura Bio, Inc. Former jobs include President, Chief Executive Officer & Director at Global Blood Therapeutics, Inc. in 2012; Chairman at Nurix Therapeutics, Inc. from 2014 to 2016; Chairman at Constellation Pharmaceuticals, Inc. from 2012 to 2021; Director at Igenica Biotherapeutics, Inc.; Assistant Director at The J.
David Gladstone Institutes; Senior Vice President at Genencor International, Inc.; Member at Roche Group; Senior Executive-in-Residence at Prospect Venture Partners; and Partner at Third Rock Ventures LLC from 2013 to 2015.
Education includes undergraduate studies at Princeton University and a doctorate from The University of California, San Francisco.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/06/2026 | 990.238 ( 0,47 % ) | 156 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Director Ejecutivo | 01/11/2014 |
Nura Bio, Inc.
 Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops neuroprotective drugs and therapies | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director Ejecutivo | 01/03/2012 |
| NURIX THERAPEUTICS, INC. | Director Ejecutivo | 18/09/2014 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Inversor de Capital Privado | 01/01/2015 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Director Ejecutivo | 17/06/2014 |
Cogentus Pharmaceuticals, Inc.
 Cogentus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Director Ejecutivo | 18/12/2009 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 14 |
|---|---|
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Develops and manufactures enzyme product solutions | Health Technology |
Cogentus Pharmaceuticals, Inc.
Cogentus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cancer | Health Technology |
Nurix Therapeutics, Inc.
 Nurix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical stage biopharmaceutical company that discovers, develops and commercializes oral, small molecule therapies for the treatment of cancer & immune disorders | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prospect Venture Partners
 Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and biomedical innovation sectors. It provides financing for seed, early and growth stage capital requirements. | Finance |
The J. David Gladstone Institutes
 The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services Engages in conducting research in biotechnology | Commercial Services |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Revolution Medicines, Inc.
 Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops neuroprotective drugs and therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
